Recombinant Human Angiopoietin-like 1 Flag-tag Protein, CF

2 μg/lane of Recombinant Human Angiopoietin‑like Protein 1/ANGPTL1 Flag-tag (Catalog# 10013-AN) was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing a predominant band at 60 kDa and 180 kDa, respectively.

When Recombinant Human Integrin alpha 1 beta 1 (Catalog # 7064-AB) is used at 1 μg/mL, Recombinant Human Angiopoietin‑like Protein 1/ANGPTL1 Flag-tag (Catalog # 10013-AN) binds with an ED50 of 8‑80 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Angiopoietin-like 1 Flag-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Integrin alpha 1 beta 1 Recombinant Human Integrin alpha 1 beta 1 (Catalog # 7064-AB) is used at 1 μg/mL, Recombinant Human Angiopoietin‑like Protein 1/ANGPTL1 binds with an ED₅₀ of 8-80 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human Angiopoietin-like Protein 1/ANGPTL1 protein
  Gly24-Asp491, with a C-terminal Flag-tag
• Accession #: O95841
• N-terminal Sequence: Arg22
• Structure / Form: Disulfide-linked oligomer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >75%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Theoretical MW: 56 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: Predominant band at 60 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris, NaCl and CHAPS with Trehalose.
• Purity: >75%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Angiopoietin-like 1 Flag-tag Protein, CF

• ANG-3
• ANG3angioarrestin
• Angiopoietin like Protein 1
• angiopoietin Y1
• angiopoietin-3
• angiopoietin-like 1
• Angiopoietin-like Protein 1
• angiopoietin-related protein 1
• ANGPT3
• ANGPTL1
• AngY
• AngY1
• ARP1
• ARP1angiopoietin 3
• dJ595C2.2 (angiopoietin Y1)
• dJ595C2.2
• KIAA0351
• UNQ162

Background

Angiopoietin like Protein 1 (ANGPTL1), also known as Angioarrestin, ARP1 and ANG3, is a secreted glycoprotein that contains a coiled coil domain at the N-terminus and a fibrinogen like domain at the C-terminus (1). ANGPTL1 is one of the seven members of the Angiopoietin-like family proteins. Similar to angiopoietins, ANGPTL1 secretes as a disulfide linked homo-oligomer (2-4). Mature human ANGPTL1 shares 94% sequence identity with its mouse homolog. ANGPTL1 is highly expressed in adrenal gland, placenta, thyroid gland, heart, skeletal muscle and small intestine, and weakly expressed in testis, ovary, colon, pancreas, kidney and stomach (1). Expression of ANGPTL1 is down-regulated in various cancers (4-6). ANGPTL1 has anti-angiogenic functions, inhibiting endothelial cell proliferation, migration, tube formation, and adhesion (4, 5). ANGPTL1 is a tumor suppressor. Over-expression of ANGPTL1 inhibits tumor growth (4, 5), migration, and metastasis (6, 7). Upon binding to integrin alpha 1/ beta 1, the FAK/Src-JAK-STAT3 signaling pathway is inhibited in hepatocellular carcinoma, promoting apoptosis and suppressing cancer invasion and angiogenesis (6). Binding to integrin alpha 1/ beta 1 also leads to the inhibition of FAK/ERK/SP1 signaling pathway to induce the expression of micro RNA 630, which suppresses the zinc finger protein SLUG to inhibit lung cancer cell mobility (7). ANGPT-L1 has been shown to directly interact with and antagonize MET receptor activity in hepatocellular carcinoma (8).

1. Kim, I. et al. (1999), FEBS Lett 443:353
2. Kim, K-T. et al. (2005) J. Biol. Chem. 280:20126.
3. Procopio, W. N., et al. (1999) J. Biol. Chem. 274:30196
4. Dhanabal, M. et al. (2002) Cancer Res 62:3834.
5. Smagur, A. et al. (2005) Acta Biochim Pol. 52:875.
6. Yan, Q. et al. (2017) Cancer Res. 77:5831.
7. Kuo, T-C. et al. (2013) J Clin Invest 123:1082.
8. Chen H-A, et al. (2016) Hematology 64(5):1637.

Bioinformatics

• Uniprot:
  • O95841()